Systemic sclerosis & Raynaud's
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial
Authors' conclusion
Data from the SENSCIS trial suggest that patients with SSc-ILD are at risk of ILD progression and benefit from nintedanib largely irrespective of their extent of fibrotic ILD at baseline.
Study context
- Population
- Patients with SSc-ILD in the SENSCIS trial
- Participants
- 288 vs 288
- Comparison
- Association of baseline extent of fibrotic interstitial lung disease (ILD) on high-resolution computed tomography (HRCT) (and its interplay with forced vital capacity (FVC) % predicted) with FVC decline over 52 weeks, in placebo and nintedanib groups
- Placebon = 288
- Nintedanibn = 288
- Primary endpoint
- Association between extent of fibrotic ILD on HRCT at baseline and decline in FVC % predicted
- Follow-up
- Week 52
Methodological detailsgeneralized additive models
- Generalized additive models
Primary result
As reported in the abstract
Correlation between baseline extent of fibrotic ILD and decline in FVC % predicted
Placebo
−0.09
r · 95% CI −0.2–0.03
Nintedanib
0.01
r · 95% CI −0.11–0.12
Further findings
Interplay of baseline extent of fibrotic ILD and FVC % predicted with FVC % predicted decline · week 52
- Placebo: higher values of both tended to be associated with greater decline
- Nintedanib: no evidence of an association
Original publication
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology (Oxford). Published 16 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →